Founder & CEO
Profile summary: Optimimed Pte Ltd • Co-Founder · Master of Business Administration - MBA at Massachusetts Institute of Technology
Iterative Health
Iterative Health accelerates gastrointestinal and hepatology clinical trials with an AI-powered platform and specialized services. The company optimizes clinical research sites to improve patient recruitment and site activation, reducing trial timelines.
Updated yesterday
Funding
Raised to date
$257MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
+7$77M · Series C
Announced Apr 2026
Disclosed cumulative: $257M
3/3
RoundDateAmountValuationInvestors
Founders
Product
Problem
Clinical trials in gastroenterology face challenges with slow patient recruitment and site activation, hindering the timely development of novel therapeutics. This inefficiency delays patient access to potentially life-saving treatments and impacts the overall success rate of research programs.
Solution
Iterative Health provides an AI-powered platform and services designed to optimize clinical trial operations and enhance gastrointestinal (GI) and hepatology research. The company focuses on empowering clinical research sites within its network to accelerate trial timelines and improve patient enrollment. By leveraging advanced technology and specialized services, Iterative Health aims to increase the efficiency and effectiveness of clinical trials, ultimately facilitating faster access to new treatments for patients.
Target Audience
The primary target audience includes clinical research sites, pharmaceutical and biotechnology companies, and contract research organizations (CROs) involved in GI and hepatology clinical trials.
Features
- AI-driven platform for clinical trial site optimization, focusing on GI and hepatology studies.
- Tech-enabled services designed to accelerate site activation and patient screening.
- Network of high-performing clinical research sites that exceed industry benchmarks for activation speed and patient enrollment.
- Data indicates 2x faster site activation and 2x speed to first patient screened compared to industry averages.
- Average site performance on IBD studies is over 4x that of industry benchmarks.
- Specialized teams with expertise in life sciences and clinical operations support strategic partnerships with sponsors.
- Facilitates trial identification, negotiation, feasibility assessment, and site selection.
- Focus areas include IBD, EoE, Celiac, GERD, NASH, MASH, PBC, PSC, Vaccines, Infectious Diseases, and Obesity.
- Offers SKOUT, an AI-powered real-time polyp detection system for colonoscopies to improve diagnostic accuracy.